Glossary CLBP chronic low back pain CKD chronic kidney disease CNS central nervous system CV cardiovascular CVD cardiovascular disease FDA Food and Drug Administration GLP-1 glucagon-like peptide-1 GLP-1s glucagon-like peptide-1 receptor agonists HF heart failure HTN hypertension MACE major adverse cardiovascular events MASH metabolic dysfunction-associated steatohepatitis OA osteoarthritis OSA obstructive sleep apnea PAD peripheral arterial disease SC subcutaneous SGLT2i sodium-glucose co-transporter 2 inhibitor sNDA supplemental New Drug Application T1DM type 1 diabetes mellitus T2DM type 2 diabetes mellitus U.S
The Cut
Speaking on "The Howard Stern Show" in January 2025, Schumer, who's said a lot about her weight loss journey, said she took Ozempic around 2022 but had to stop because it resulted in severe nausea
Part of the issue is that the approved form of semaglutide can be acquired only from Novo Nordisk, the patent holder for Ozempic and Wegovy, and the company doesn't share drug ingredients with compounding pharmacists, Susan McCoy , executive director of the Mississippi Board of Pharmacy, told NBC News
Paul Kolodzik returns to The AGEIST Podcast to discuss his pioneering work around GLP-1s: using these medications to help people reduce their alcohol intake
Gastrointestinal effects represent the primary concern